Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Yanagawa, Masumi ^a   Ikemot, Kenzo ^a   Kawauchi, Shigeto ^a   Furuya, Tomoko ^a   Yamamoto, Shigeru ^a   Oka, Masaaki ^a   Oga, Atunori ^a   Nagashima, Yukiko ^b   Sasaki, Kohsuke ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Division of Breast Disease Surgery   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST TUMOR; CANCER GRADING; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CLASSIFICATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; GENOTYPE; HUMAN; HUMAN GENOME; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANEUPLOIDY; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DNA, NEOPLASM; FEMALE; GENOME, HUMAN; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; RECEPTOR, ERBB-2;

EID: 84864686999     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-376     Document Type: Article

References (37)

1. Molecular evolution of breast cancer. Reis-Filho JS, Simpson PT, Gale T, Lakhani SR, J Pathol 2005 205 248 254 10.1002/path.1691 15641021 (Pubitemid 40227995)
2. Recent adavances in systemic therapy new diagnostics and biological predictors of outcome in early breast cancer. Oakman C, Bessi S, Zatarana E, Galardi F, Biganzoli L, Di Leo A, Breast Cancer Res 2009 11 205 10.1186/bcr2238 19435470
3. Emerging therapeutic targets in breast cancer bone metastasis. Rose ANN, Siegel PM, Future Oncol 2010 6 55 74 10.2217/fon.09.138 20021209
4. From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change? Raica M, Jung I, Cimpean AM, Suciu C, Muresan AM, Rpm J Mrphol Embryol 2009 50 5 13
5. Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Ann Oncol 2011 22 1736 1747 10.1093/annonc/mdr304 21709140
6. Basal-like breast cancer defined by five biomarkers has superior prgnostic value than triple-negative phenotype. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO, Clin Cancer Res 2008 14 1368 1376 10.1158/1078-0432.CCR-07-1658 18316557 (Pubitemid 351413917)
7. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Tang P, Skinner KA, Hicks DG, Diagn Mol Pathol 2009 18 125 132 10.1097/PDM.0b013e31818d107b 19704256
8. Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Bayani J, Selvarajah S, Maire G, Vukovic B, Al-Romaih K, Zielenska M, Squire JA, Semin Cancer Biol 2007 17 5 18 10.1016/j.semcancer.2006.10.006 17126026 (Pubitemid 46084849)
9. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Haroske G, Baak JP, Danielsen H, Giroud F, Gschwendtner A, Oberholzer M, Reith A, Spieler P, Böcking A, Anal Cell Pathol 2001 23 89 95 11904464 (Pubitemid 34451106)
10. Clinical applications of image cytometry to human tumour analysis. Millot C, Dufer J, Histol Histopathol 2000 15 1185 2000 11005244
11. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Suehiro Y, Okada T, Okada T, Anno K, Okayama N, Ueno K, Hiura M, Nakamura M, Kondo T, Oga A, Kawauchi S, Hirabayashi K, Numa F, Ito T, Saito T, Sasaki K, Hinoda Y, Clin Cancer Res 2008 14 3354 3361 10.1158/1078-0432.CCR-07-4609 18519763
12. Image DNA cytometry in FNABs of Libyan breast disease. Abdalla FB, Boder JM, Buhmeida A, Elzaagheid A, Collan Y, Anticancer Res 2010 30 175 181 20150633
13. The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer. Yildirim Assaf S, Coumbos A, Hopfenmüller W, Foss H-D, Stein H, Kühn W, J Clin Pathol 2007 60 649 655 10.1136/jcp.2005.035550 17557867 (Pubitemid 46975219)
14. Relation of invasive ductal carcinoma by chromosome instability and breast cancer-related markers. Ikemoto K, Furuya T, Oga A, Kawauchi S, Sasaki K, J Jpn Soc Clin Cytol 2007 46 332 337 10.5795/jjscc.46.332
15. Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima H, Kajiwara H, Akiyama F, Breast Cancer 2006 13 232 235 10.2325/jbcs.13.232 16929115
16. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S, J Oncol Pract 2010 6 195 197 10.1200/JOP.777003 21037871
17. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO, J Natl Cancer Inst 2009 101 736 750 10.1093/jnci/djp082 19436038
18. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H, J Clin Oncol 2009 27 2809 2815 10.1200/JCO.2008.18.2808 19380452
19. A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. Colleoni M, Bagnardi V, Rotmensz N, Viale G, Mastropasqua M, Veronesi P, Cardillo A, Torrisi R, Luini A, Goldhirsch A, Eur J Cancer 2010 46 2216 2224 10.1016/j.ejca.2010. 04.008 20471822
20. The Relationship of DNA ploidy to chromosomal Instability in primary human colorectal cancers. Miyazaki M, Furuya T, Shiraki A, et al. Cancer Res 1999 59 5283 5285 10537310 (Pubitemid 29503995)
21. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Furuya T, Uchiyama T, Murakami T, Sato T, Oga A, Sasaki K, Clin Cancer Res 2000 6 2815 2820 10914729 (Pubitemid 30482122)
22. Biological characteristics in bladder cancer depend on the type of genetic instability. Yamamoto Y, Matsuyama H, Kawauchi S, et al. Clin Cancer Res 2006 12 2752 2758 10.1158/1078-0432.CCR-05-0805 16675567
23. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Comparison with DNA ploidy. Sasaki K, Matsumura K, Murakami T, Tsuji T, Oncology 1992 49 147 153 10.1159/000227029 1574251
24. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M, Cancer 1988 62 989 993 10.1002/1097-0142(19880901)62:5<989::AID- CNCR2820620525>3.0.CO;2-U 3409179
25. Breast cancer subtypes and the risk of local and regional relapse. Voduc KD, Cheang MC, Tydesley S, Geimon K, Nielsen TO, Kennecke H, J Clin Oncol 2010 28 1684 1691 10.1200/JCO.2009.24.9284 20194857
26. Genetic instability in colorectal cancers. Lengauer C, Kinzler KW, Vogelstein B, Nature 1997 386 623 627 10.1038/386623a0 9121588 (Pubitemid 27175430)
27. Genetic instabilities in huma cancers. Lengauer C, Kinzler KW, Vogelstein B, Nature 1998 396 643 649 10.1038/25292 9872311 (Pubitemid 29003936)
28. DNA copy number aberrations associated with aneuploidy and chromosomal instability in breast cancers. Kawauchi S, Furuya T, Ikemoto K, Nakao M, Yamamoto S, Oka M, Sasaki K, Oncol Rep 2010 24 875 883 20811667
29. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Smid M, Hoes M, Sieuwerts AM, Sleifer S, Zhang Y, Wang Y, Foekens JA, Martens JW, Breast Cancer Res Treat 2011 128 23 30 10.1007/s10549-010-1026-5 20632083
30. Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer. Li L, Mu K, Zhou G, Lan L, Auer G, Zetterberg A, Br J Cancer 2008 99 513 519 10.1038/sj.bjc.6604479 18665192
31. Aneuploidy-cancers fatall flaw? Williams BR, Amon A, Cancer Res 2009 69 5289 5291 10.1158/0008-5472.CAN-09-0944 19549887
32. Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Toft DJ, Cryns VL, Mol Endocrinol 2011 25 199 211 10.1210/me.2010-0164 20861225
33. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z, Nat Genet 2006 38 1043 1048 10.1038/ng1861 16921376 (Pubitemid 44325930)
34. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RK, Ma Y, Krüger S, Bruch HP, Auer G, Guo NL, Ried T, Int J Cancer 2009 124 1552 1564 10.1002/ijc.24017 19101988
35. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C, Cancer Res 2011 71 3447 3452 10.1158/0008-5472.CAN-10-3667 21270108
36. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C, Cancer Epidemiol Biomarkers Prev 2011 20 2183 2194 10.1158/1055-9965.EPI-11-0343 21784954
37. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ, Arch Pathol Lab Med 2000 124 966 978 10888772